Intramural duodenal hematoma following upper gastrointestinal endoscopic biopsy

1989 ◽  
Vol 34 (2) ◽  
pp. 289-291 ◽  
Author(s):  
Stylianos A. Zinelis ◽  
Lee M. Hershenson ◽  
Michael F. Ennis ◽  
Mariella Boller ◽  
Farhad Ismail-Beigi
2002 ◽  
Vol 14 (4) ◽  
pp. 152-155 ◽  
Author(s):  
Carlos A. Cappellanes ◽  
Kiyoshi Hashiba ◽  
Horus A. Brasil ◽  
Marco A. D’Assunção ◽  
Daniel Moribe ◽  
...  

Medicina ◽  
2020 ◽  
Vol 56 (7) ◽  
pp. 363
Author(s):  
Lubomir Mihalkanin ◽  
Branislav Stancak

Background and objectives: Although treatment with novel oral non-vitamin K antagonist 3anticoagulants (NOACs) is associated with an overall decrease in hemorrhagic complications compared to warfarin, the incidence of gastrointestinal bleeding remains contradictory. Materials and Methods: After the exclusion of patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years) was randomly divided into four equivalent groups, treated with dabigatran, rivaroxaban, apixaban, or warfarin. Patients were prospectively followed up for three months of treatment, with a focus on anamnestic and endoscopic signs of bleeding. In addition, bleeding risk factors were evaluated. Results: In none of the patients treated with warfarin or NOACs was any serious or clinically significant bleeding recorded within the follow-up period. The incidence of clinical bleeding and endoscopically detected bleeding in the upper GT after three months of treatment was not statistically different among groups (χ2 = 2.8458; p = 0.41608). The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding (p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor (p = 0.206; Spearman’s correlation coefficient = 0.205). We did not record any post-biopsy continued bleeding. Conclusions: No significant GIT bleeding was found in any of the treatment groups, so we consider it beneficial to perform routine EGD before the initiation of any anticoagulant therapy in patients with an increased risk of upper GIT bleeding. Detection and eradication of HP as well as preventive PPI treatment may mitigate the occurrence of endoscopic bleeding. Endoscopic biopsy during the NOAC treatment is safe.


1993 ◽  
Vol 16 (2) ◽  
pp. 183-185 ◽  
Author(s):  
A. L. Appleton ◽  
L. Sviland ◽  
A. D. J. Pearson ◽  
M. A. Green ◽  
E. J. Eastham ◽  
...  

1970 ◽  
Vol 4 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Md Din-ul Islam ◽  
Sufi HZ Rahman ◽  
SM Shamsuzzaman ◽  
Naima Muazzaman ◽  
Nasim Ahmed ◽  
...  

The present study was conducted in the department of Microbiology, Dhaka Medical College, Dhaka during the period of January, 2007 to December, 2007. Urine samples were collected from 86 dyspeptic patients undergoing upper Gastrointestinal Tract (GIT) endoscopy to determine anti-H. pylori IgG antibody by an ELISA method. Gastric biopsy tissues were tested for culture, rapid urease test and H&E/Giemsa stain. Out of 86 endoscopic biopsy specimens, 45 (52.33%) were culture positive, 63 (73.26%) were rapid urease test positive and 64 (74.42%) were H&E/Giemsa stained positive for H. pylori. According to operational standard definition, among the 86 study population, 66 (76.74%) were H. pylori infected, 16 (18.60%) were uninfected and 4 (4.65%) were indeterminate. Among 66 H. pylori infected cases, 63 (95.45%) were urine ELISA positive and among 16 uninfected cases 3 (18.75%) were urine ELISA positive. Out of 86 study population, 66 (76.74%) were urine ELISA positive. The sensitivity, specificity, PPV, NPP and accuracy of urine ELISA were 95.45%, 81.25%, 95.45%, 81.25% and 92.68% respectively. The result of the study shows that H. pylori infection can be rapidly and reliably diagnosed by detecting anti-H. pylori IgG from urine. Key words: H. pylori; ELISA; GIT; IgG. DOI: http://dx.doi.org/10.3329/bjmm.v4i1.8463 BJMM 2011; 4(1): 14-17


2020 ◽  
Vol 50 (3) ◽  
Author(s):  
Claudio Iglesias ◽  
Paul Puglia ◽  
Diego Pereira Núñez

The intramural duodenal hematoma is a rare but well-known collateral complication after an endoscopic biopsy. It is more frequent after abdominal trauma or therapeutic endoscopy and even more in anticoagulant-treated patients or those with coagulation disorders. Clinical presentation consists of the symptoms and the signs of the intestinal obstruction, the pancreatitis and the conjugated hyperbilirubinemia. We report a pediatric case of a five-year-old female patient who was being checked for celiac disease. Without known previous bleeding or coagulation disorders, she presented a intramural duodenal hematoma with pancreatitis as a complication of the endoscopic biopsy procedure. A summary of the symptomatology and the signs, the diagnosis, the conservative treatment and evolution is described and also a reminder to paediatric endoscopists to be aware that this unusual complication can occur. This case presents the possibility that an intramural duodenal hematoma can be a complication of a duodenal endoscopic biopsy in patients with no coagulations disorders. This hematoma subsided with a non-surgical treatment (conservative), assisted by the joint work of a pediatric gastroenterologist and surgeon.


JMS SKIMS ◽  
2010 ◽  
Vol 13 (1) ◽  
pp. 23-24
Author(s):  
Gull Mohd Bhat ◽  
Shiekh Aejaz Aziz ◽  
A R Lone ◽  
Manzoor Ahmad Banday ◽  
Syed Nissar Ahmad

A young adult with of GCT of testis developing recurrence in the form of duodenal metastasis is discussed. Till now only a few similar cases are reported in literature. J Med Sci 2010;13(1):23-24


Sign in / Sign up

Export Citation Format

Share Document